Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies

Background: Recent randomized controlled trials have demonstrated that immune checkpoint inhibitors (ICIs) improve patient outcomes, but whether these novel agents are cost-effective for untreated advanced renal cell carcinoma (aRCC) remains unclear. Materials and Methods: A microsimulation model wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, SiNi, Li, JianHe, Peng, LiuBao, Li, YaMin, Wan, XiaoMin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458866/
https://www.ncbi.nlm.nih.gov/pubmed/34566643
http://dx.doi.org/10.3389/fphar.2021.718014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458866/
https://www.ncbi.nlm.nih.gov/pubmed/34566643
http://dx.doi.org/10.3389/fphar.2021.718014

Ejemplares similares